Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer -- MAY 29-JUN 02, 2015 -- Chicago, ILWOS: 000358036902497Amer Soc Clin Onco
Cancer is currently the second leading killer disease. There are many different kinds of cancer that...
Cabazitaxel, a novel chemotherapeutic taxane, is effective against docetaxel-resistant cells and tum...
<div><p>Background</p><p>Glioblastoma (GBM) is the most common primary brain malignancy in adults, y...
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on P...
Cabazitaxel is a second-generation semisynthetic taxane. The recognized anti-neoplastic effect of Ca...
Taxanes target microtubules and are clinically established chemotherapeutic agents with proven effic...
Adrenocortical cancer (ACC) is a rare and aggressive malignancy with a poor prognosis. The overall 5...
Adrenocortical cancer (ACC) is a rare and aggressive malignancy with a poor prognosis. The overall 5...
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on P...
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on P...
This Phase I dose-escalation study (GASTANA) evaluated the safety, tolerability, pharmacokinetics an...
Background: Celecoxib, a cyclooxygenase-2 inhibitor has been found to inhibit the proliferation of s...
Glioblastoma (GBM) is the most common primary brain malignancy in adults, yet survival outcomes rema...
Glioblastoma is a fatal primary malignant brain tumor, and the 5-year survival rate of treated gliob...
The aim of our study was to determine the effect of selected cytostatics on a human ovarian cancer c...
Cancer is currently the second leading killer disease. There are many different kinds of cancer that...
Cabazitaxel, a novel chemotherapeutic taxane, is effective against docetaxel-resistant cells and tum...
<div><p>Background</p><p>Glioblastoma (GBM) is the most common primary brain malignancy in adults, y...
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on P...
Cabazitaxel is a second-generation semisynthetic taxane. The recognized anti-neoplastic effect of Ca...
Taxanes target microtubules and are clinically established chemotherapeutic agents with proven effic...
Adrenocortical cancer (ACC) is a rare and aggressive malignancy with a poor prognosis. The overall 5...
Adrenocortical cancer (ACC) is a rare and aggressive malignancy with a poor prognosis. The overall 5...
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on P...
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on P...
This Phase I dose-escalation study (GASTANA) evaluated the safety, tolerability, pharmacokinetics an...
Background: Celecoxib, a cyclooxygenase-2 inhibitor has been found to inhibit the proliferation of s...
Glioblastoma (GBM) is the most common primary brain malignancy in adults, yet survival outcomes rema...
Glioblastoma is a fatal primary malignant brain tumor, and the 5-year survival rate of treated gliob...
The aim of our study was to determine the effect of selected cytostatics on a human ovarian cancer c...
Cancer is currently the second leading killer disease. There are many different kinds of cancer that...
Cabazitaxel, a novel chemotherapeutic taxane, is effective against docetaxel-resistant cells and tum...
<div><p>Background</p><p>Glioblastoma (GBM) is the most common primary brain malignancy in adults, y...